Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • IT / Health Venture
    • Reckitt Benckiser...

    Reckitt Benckiser names PepsiCo executive Laxman Narasimhan as next CEO

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-13T09:30:12+05:30  |  Updated On 13 Jun 2019 9:30 AM IST
    Reckitt Benckiser names PepsiCo executive Laxman Narasimhan as next CEO

    Laxman Narasimhan (52) would join RB as CEO-designate and then would be appointed to the board of the company as an Executive Director with effect from July 16, 2019, said a company statement, which own brands which include Dettol, Durex, Harpic, Harpic and Air Wick.


    New Delhi: UK-based global FMCG major Reckitt Benckiser on Wednesday named PepsiCo executive Laxman Narasimhan as its next Chief Executive Officer succeeding Rakesh Kapoor.


    Narasimhan (52) would join RB as CEO-designate and then would be appointed to the board of the company as an Executive Director with effect from July 16, 2019, said a company statement, which own brands which include Dettol, Durex, Harpic, Harpic and Air Wick.


    The India-origin executive will become Group CEO with effect from September 1, 2019, it added.


    Narasimhan would succeed Kapoor, who has been leading RB as CEO since 2011.


    Read Also: Reckitt Benckiser chief Rakesh Kapoor to step down


    Reckitt Benckiser in January had announced that Kapoor would retire as CEO by the end of 2019 after a 32-year stint at the firm.


    Commenting on the development Chris Sinclair, Chairman of the Board said: "The Board is delighted to have appointed Laxman as our new Chief Executive Officer after a thorough and rigorous global selection process from a strong bench of internal and external candidates."


    Narasimhan is present with the US-based global food & beverage giant PepsiCo, where he is currently the Global Chief Commercial Officer.


    He has been a member of the PepsiCo executive committee for the last four years reporting to the Chairman and Chief Executive.


    Narasimhan leads Strategy, Global Category Groups, Global R&D and is implementing an advanced digital capability across the PepsiCo business.


    He will serve as Group Chief Executive Officer at RB, while also directly leading the Health Business Unit.


    As CEO of RB, Narasimhan will receive a salary of £ 950,000, the company said.


    Read Also: HC Relief to Reckitt Benckiser in advertisement of ASU drugs case


    Besides, he will also receive a pension allowance of 10 per cent of salary in line with the wider RB workforce in the UK and other benefits in line with RB Policy.


    "He will be eligible to participate in the Company's existing annual bonus plan with a target of 120 per cent of salary... He will receive an initial LTIP grant of 75,000 shares and 150,000 options, for the three-year performance period 2019-2021, followed by a two-year holding period," it added.

    Air WickCEOconsumer productsdettolDurexHarpicHealthcareLaxman NarasimhanLaxman reckittLTIP grantPepsiCoReckittReckitt Benckiserreckitt ceo
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok